USBC, Inc 8-K, filed Jun 22, 2021
USBC, Inc. (USBC)
8-K
2021-06-22
For: 2021-06-22
View Original
Added on
April 10, 2026
About this 8-K
USBC, Inc filed this 8-K on June 22, 2021.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): June 22,
2021
KNOW LABS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-30262
|
90-0273142
|
|
(State
of other jurisdiction
|
(Commission
|
(IRS
Employer
|
|
of
incorporation)
|
File
Number)
|
Identification
No.)
|
500 Union Street, Suite 810
Seattle, Washington 98101
(Address
of principal executive office)
(206) 903-1351
(Registrant’s
telephone number, including area code)
(Former
name, former address and former fiscal year, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a -12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Securities
registered pursuant to Section 12(b) of the Act: None
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company. ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other
Events.
On June
22, 2021, Know Labs, Inc. (the “Company”), an emerging
leader in non-invasive medical diagnostics, announced that it had
received U.S. Patent No. 11,033,208 that was issued by the United
States Patent and Trademark Office and is titled “Fixed
Operation Time Frequency Sweeps for an Analyte Sensor.” The
patent relates to how operation of the Know Labs Bio-RFID sensor
technology is controlled. The sensing routines conducted by the
sensor to non-invasively detect an analyte in the body are
conducted substantially identically to one another, which means
results are obtained under as close to identical conditions as
possible. This allows for a more accurate comparison between the
results of each sensing routine, increasing the precision and
accuracy of the Know Labs Bio-RFID sensor technology in
non-invasively measuring and identifying a variety of analytes,
including glucose.
A copy of the press release is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
|
Exhibit No.
|
|
Description
|
|
|
Press release
dated June 22, 2021. Filed herewith.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
Registrant:
KNOW LABS, INC.
|
|
|
|
|
|
|
|
|
June 22,
2021
|
By:
|
/s/
Ronald
P. Erickson
|
|
|
|
|
Ronald P.
Erickson
|
|
|
|
|
Chairman of the
Board
|
|
Exhibit 99.1
Know Labs Receives New Patent for Its Non-Invasive
Diagnostic
Technology Platform, Bringing Patents Issued and Pending to Nearly
60
SEATTLE
– June 22, 2021 -- Know Labs, Inc. (OTCQB: KNWN), an emerging
leader in non-invasive medical diagnostics, today announced it has
been granted an additional patent for its Bio-RFIDTM technology,
growing its substantial patent portfolio to 57 issued and pending
patents, an important milestone for the company.
“We
are building a breakthrough platform technology that will
revolutionize medical diagnostics, beginning with what we believe
will be the world’s first non-invasive glucose monitoring
device,” said Phil Bosua, Know Labs CEO and Bio-RFID
inventor. “This patent is critical because without the
ability to control the timing of the frequency capture, accurate
non-invasive measurements using radio frequency on the human body
are not possible. We’ve been granted 22 patents to date and
have 35 more pending. Our advances will lead to breakthroughs in
diagnostics and potentially disease prevention, so we are pursuing
and delivering on a disciplined intellectual property strategy to
protect our innovative technology and its
value.”
U.S. Patent No. 11,033,208 was issued by the United States
Patent and Trademark Office and is titled “Fixed Operation
Time Frequency Sweeps for an Analyte Sensor.” The patent relates to
how operation of the Know Labs Bio-RFID sensor technology is
controlled. The sensing routines conducted by the sensor to
non-invasively detect an analyte in the body are conducted
substantially identically to one another, which means results are
obtained under as close to identical conditions as
possible. This allows for a more accurate comparison between
the results of each sensing routine, increasing the precision and
accuracy of the Know Labs Bio-RFID sensor technology in
non-invasively measuring and identifying a variety of analytes,
including glucose.
Know
Labs recently reported successful results from an independent
pre-clinical study validating the company’s Bio-RFID
technology. This newly issued patent demonstrates the accuracy and
sensitivity of the sensor, which is necessary for successful FDA
clinical trials for the company’s non-invasive blood glucose
monitor.
Know
Labs will continue to align its product development efforts with
its intellectual property strategy. The company continues to file
new patents regularly and will provide further detail on the scope
and reach of its intellectual property portfolio as patents are
issued.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade under
the stock symbol “KNWN.” The Company’s technology
uses spectroscopy
to direct electromagnetic energy through a substance or material to
capture a unique molecular signature. The Company refers to its
technology as Bio-RFID™. The Bio-RFID technology can be
integrated into a variety of wearable, mobile or bench-top form
factors. This patented and patent pending technology makes it
possible to effectively conduct analyses that could only previously
be performed by invasive and/or expensive and time-consuming
lab-based tests. The first application of our Bio-RFID technology
will be in a product marketed as a glucose monitor. It will provide
the user with real time information on their blood glucose levels.
This product will require US Food and Drug Administration approval
prior to its introduction to the market.
Safe Harbor Statement
This
release contains statements that constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. These statements appear in a number of places in this
release and include all statements that are not statements of
historical fact regarding the intent, belief or current
expectations of Know Labs, Inc., its directors or its officers with
respect to, among other things: (i) financing plans; (ii) trends
affecting its financial condition or results of operations; (iii)
growth strategy and operating strategy; and (iv) performance of
products. You can identify these statements by the use of the words
“may,” “will,” “could,”
“should,” “would,” “plans,”
“expects,” “anticipates,”
“continue,” “estimate,”
“project,” “intend,” “likely,”
“forecast,” “probable,”
“potential,” and similar expressions and variations
thereof are intended to identify forward-looking statements.
Investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and
uncertainties, many of which are beyond Know Labs, Inc.’s
ability to control, and actual results may differ materially from
those projected in the forward-looking statements as a result of
various factors. These risks and uncertainties also include such
additional risk factors as are discussed in the Company’s
filings with the U.S. Securities and Exchange Commission, including
its Annual Report on Form 10-K for the fiscal year ended September
30, 2020, Forms 10-Q and 8-K, and in other filings we make with the
Securities and Exchange Commission from time to time. These
documents are available on the SEC Filings section of the Investor
Relations section of our website at www.knowlabs.co. The Company
cautions readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
The Company undertakes no obligation to update any forward-looking
statement to reflect events or circumstances after the date on
which such statement is made.
Know Labs, Inc. Contact:
Jordyn
(Theisen) Hujar
jordyn@knowlabs.co
Ph.
(206) 629-6414